Real-life Data of Constitutional Von Willebrand Disease in Western France (HOPSCOTCH-II)

Nantes University Hospital (NUH)

Status: Completed

Conditions: Von Willebrand Diseases

Treatments: Other: no intervention

Study type: Observational

Funder types: Other

Identifiers

NCT04887324

RC21_0188

Details and patient eligibility

About

The objective of this observational study HOPSCOTcH-WILL II is to provide an accurate and detailed account of current Von Willebrand Disease (VWD) therapeutic management by collecting real-life data on hemorrhagic treated events in the 5 Western French Hemophilia Treatment Center.

The HOPSCOTCH-WILL II study aims to describe therapeutic management of patients with VWD, following the provision of a recombinant drug in France; It will also permit to carry out a budget impact analysis to quantify the economic significance of this new era.

Enrollment: 922 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Constitutional Von Willebrand Disease patient, of any severity, with or without Von Willebrand Factors inhibitors
• Patient included in the research database BERHLINGO
• Patient treated or not by desmopressin or Von Willebrand Factor/FVIII/by-passing agents available on the French market (at baseline)
• Patient who agrees to participate in the HOPSCOTcH-Will II and followed in one of the 5 investigator centers

Exclusion criteria

• Patients under guardianship